Thursday, July 30, 2015

Tuesday Features

Matinas BioPharma moves focus to anti-infectives

Matinas BioPharma moves focus to anti-infectives

After moving a novel omega-3 program through a successful Phase 2 program, Matinas BioPharma Holdings (OTCQB:MTNB) is now advancing two anti-infective drug candidates in the war against drug resistance. Roelof Rongen “Our initial focus is to take powerful, but sparingly used, anti-fungal and anti-bacterial drugs and increase their safety and potency,”... [Read more of this feature]


Xenon still committed to TV-45070 for neuropathic pain

Xenon still committed to TV-45070 for neuropathic pain

Xenon Pharmaceuticals (NASDAQ:XENE) and its development and commercialization partner, Teva Pharmaceutical Industries (NYSE, TASE:TEVA), remain fully committed to the development of TV-45070 for neuropathic pain indications, even though it failed a Phase 2b study in pain due to osteoarthritis (OA) of the knee. Dr. Simon Pimstone “We and Teva believe... [Read more of this feature]


In conversation with Heather Morehouse Ettinger

In conversation with Heather Morehouse Ettinger

Heather Morehouse Ettinger As a partner in the law firm of Troutman Sanders LLP, Heather Morehouse Ettinger focuses her practice on intellectual property due diligence and transaction drafting, intellectual property litigation, and patent counseling and procurement in the biotechnology and pharmaceutical fields. She regularly handles domestic and international... [Read more of this feature]


More Posts From Tuesday Features

Briefs

HCW starts Semler Scientific at buy

HCW starts Semler Scientific at buy

H.C. Wainwright has launched coverage of Semler Scientific (NASDAQ:SMLR) with a “buy” rating and a 12-month price target of $8. The stock closed at $3.20 on Tuesday. Semler is a medical diagnostics company that is marketing a patented device for the risk assessment of peripheral arterial disease (PAD) and other vascular conditions. Known as FloChec,... [Read more of this brief]


Amarantus study of MSPrecise published in GENE

Amarantus study of MSPrecise published in GENE

Data on Amarantus Diagnostics’ next generation sequencing molecular diagnostic test for multiple sclerosis, MSPrecise, has been published in the Elsevier journal, GENE. MSPrecise is a proprietary next-generation DNA sequencing assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS). A blood-based version of the... [Read more of this brief]


Analysts raise price target for LeMaitre Vascular

Analysts raise price target for LeMaitre Vascular

Canaccord Genuity and Roth Capital Partners have raised their price targets for LeMaitre Vascular (NASDAQ:LMAT) to $14.50 from $13, and to $14 from $11, respectively, after the company set another record sales quarter. The stock closed at $11.24 on Tuesday. “We continue to view LeMaitre as one of the most undervalued small-cap stocks in med-tech,... [Read more of this brief]


Roth starts Tracon Pharma at buy

Roth starts Tracon Pharma at buy

Roth Capital Partners has initiated coverage of Tracon Pharmaceuticals (NASDAQ:TCON) with a “buy” rating and $18 price target, calling the company an intriguing play in the $16-billion anti-VEGF market. The stock closed at $12.58 on Tuesday. Tracon is developing an antibody targeting the endoglin receptor. Endoglin is essential to the process of... [Read more of this brief]


Novadaq Q2 revenue climbs 35%

Novadaq Q2 revenue climbs 35%

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has posted revenue of $15.1-million for the second quarter, an increase of 35% from $11.2-million a year ago. Product sales rose by $3.9-million, or 38%, primarily due to a 64% increase in recurring revenue and a 24% increase in capital sales. “At the start of the year, we initiated our transformation... [Read more of this brief]


More Posts From Briefs
Email Newsletters with Constant Contact
Google+